Evidence map›Paper›PMID 40071131›Full record

ArticleFrontiers in allergy2025

Polymerised mite allergoids with glutaraldehyde reduce proteolytic activity and enhance the stability of allergen mixtures: a proof of concept with grass mixtures.

José Ignacio Tudela, Irene Soria, Eva Abel-Fernández, José Fernando Cantillo, Enrique Fernández-Caldas, José Luis Subiza, Salvador Iborra

Abstract read
In one paragraph

Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

José Ignacio Tudela *R&D Department, Inmunotek, Alcalá de Henares, Spain.
Irene Soria *R&D Department, Inmunotek, Alcalá de Henares, Spain.
Eva Abel-FernándezR&D Department, Inmunotek, Alcalá de Henares, Spain.
José Fernando CantilloR&D Department, Inmunotek, Alcalá de Henares, Spain.
Enrique Fernández-CaldasR&D Department, Inmunotek, Alcalá de Henares, Spain.
José Luis SubizaR&D Department, Inmunotek, Alcalá de Henares, Spain.
Salvador IborraR&D Department, Fundación Inmunotek, Alcalá de Henares, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Polysensitized patients require allergen immunotherapy (AIT) targeting multiple allergens. However, combining allergen extracts can lead to instability and reduced efficacy particularly due to the high proteolytic activity of house dust mite (HDM) allergens. While is known that glutaraldehyde cross-linking may reduce enzymatic activity, its ability to stabilize multi-allergen formulations and protect key allergens from degradation remains unexplored. Objective: To evaluate the impact of glutaraldehyde polymerization on the stability and immunogenicity of HDM and grass pollen allergen formulations, addressing proteolytic activity challenges in multi-allergen vaccines. Methods: Stability was assessed over 24 months through protein quantification and antigenic activity assays. Proteolytic activity of HDM-containing extracts was measured using Azocoll, and peptide substrate-based enzymatic assays. Grass pollen allergen degradation was evaluated by SDS-PAGE, immunoblotting, and ELISA Immunogenicity was assessed in mice immunized with grass allergoids alone or in combination with glutaraldehyde-polymerised HDM, measuring IgG responses, splenocyte proliferation, and IL-10 production. Results: Glutaraldehyde polymerization significantly reduced HDM proteolytic activity ( Conclusions: Polymerised allergen extracts address the challenges of proteolytic degradation in multi-allergen formulations, offering stable, immunogenic vaccines that maintain efficacy and provide a reliable treatment option for polyallergic patients.

Indexed as

allergen immunotherapy (AIT)grass pollen allergenshouse dust mitemulti-allergen vaccinespolymerised allergenspolysensitized patientsproteolytic activity

Identifiers

PMID40071131
PMCPMC11893842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.